Browsing by Author "Amaral, Giovanna Araujo"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- COVID-19 vaccinations: summary guidance for Cancer patients in 28Languages: breaking barriers to Cancer patient InformationPublication . Mauri, Davide; Kamposioras, Konstantinos; Tsali, Lampriani; Dambrosio, Mario; De Bari, Berardino; Hindi, Nadia; Salembier, Carl; Nixon, Joanna; Dimitrios, Tzachanis; Alongi, Flippo; Hameed, Hassan; Valachis, Antonios; Papadimitriou, Konstantinos; Corradini, Stefanie; Popovic, Lazar; Kopecky, Jindrich; Rodriguez, Andres; Antunac, Katarina; Yi, Junlin; Lovey, Jozsef; Strojan, Primoz; Saraireh, Haytham; Røtterud, Ranveig; Chojnacka, Marzanna; Olalla, Santa Cruz; Chilingirova, Natalia; De Mello, Ramon Andrade; Amaral, Giovanna Araujo; Arbabi, Farsid; Vidra, Radu; Rapushi, Erjeta; Takeuchi, Dan; Christopoulos, Chirstos; Ivanova, Irina; Djan, Igor; Petricevic, Branka; Cellini, Francesco; Mihaylova, Iglika; Plavetic, Natalija Dedic; Kuhar, Cvetka Grašič; Takeuchi, Elena; Kountourakis, Pantelis; Ntellas, Panagiotis; Gazouli, Ioanna; Gkoura, Stefania; Yuce, Salih; ER, Özlem; Yasmina, Chait; Kumaran, Gireesh; Spahiu, Orges; Yusuf, Aasim; Gono, Paulina; Apostolidis, Kathi; Tolia, MariaBackground: Covid-19 vaccination has started in the majority of the countries at the global level. Cancer patients are at high risk for infection, serious illness, and death from COVID-19 and need vaccination guidance and support. Guidance availability in the English language only is a major limit for recommendations' delivery and their application in the world's population and generates information inequalities across the different populations. Methods: Most of the available COVID-19 vaccination guidance for cancer patients was screened and scrutinized by the European Cancer Patients Coalition (ECPC) and an international oncology panel of 52 physicians from 33 countries. Results: A summary guidance was developed and provided in 28 languages in order to reach more than 70 percent of the global population. Conclusion: Language barrier and e-guidance availability in the native language are the most important barriers when communicating with patients. E-guidance availability in various native languages should be considered a major priority by international medical and health organizations that are communicating with patients at the global level.
- Immunotherapy in patients with advanced non-small cell lung cancer lacking driver mutations and future perspectivesPublication . De Mello, Ramon Andrade Bezerra; Voscaboinik, Rafael; Luciano, João Vittor Pires; Cremonese, Rafaela Vilela; Amaral, Giovanna Araujo; Castelo-Branco, Pedro; Antoniou, GeorgiosFrom a complete literature review, we were able to present in this paper what is most current in the treatment with immunotherapy for advanced non-small cell lung cancer (NSCLC). Especially the use of immunotherapy, particularly inhibitors of PD-1 (programmed cell death protein 1), PDL-1 (programmed cell death protein ligand 1), and CTLA-4 (cytotoxic T-lymphocyte antigen 4). Since 2015, these drugs have transformed the treatment of advanced NSCLC lacking driver mutations, evolving from second-line therapy to first-line, with excellent results. The arrival of new checkpoint inhibitors such as cemiplimab and the use of checkpoint inhibitors earlier in the therapy of advanced and metastatic cancers has been making the future prospects for treating NSCLC lacking driver mutations more favorable and optimistic. In addition, for those patients who have low PDL-1 positivity tumors, the combination of cytotoxic chemotherapy, VEGF inhibitor, and immunotherapy have shown an important improvement in global survival and progression free survival regardless the PDL-1 status. We also explored the effectiveness of adding radiotherapy to immunotherapy and the most current results about this combination. One concern that cannot be overlooked is the safety profile of immune checkpoint inhibitors (ICI) and the most common toxicities are described throughout this paper as well as tumor resistance to ICI.